Advanced Therapy Medicinal Product Market Size
Global Advanced Therapy Medicinal Product(ATMP) Market reached USD 43.09 billion in 2025 and is expected to reach USD 174.31 Billion by 2035, growing at a CAGR of 16.8% during the forecast period 2026-2035.
Advanced therapy medicinal products (ATMPs) are medicines produced from genes, tissues, or cells. They offer new opportunities for the treatment of disease and injury. The ATMPs are classified into gene therapy medicines, somatic cell therapy medicines, and tissue-engineered medicines.
Advanced therapy medicinal products (ATMPs) constitute an innovative class of heterogeneous research-driven biopharmaceuticals. The drugs are based on cell and gene therapy; when combined with medical devices, these therapies are called tissue-engineered products.
Advanced Therapy Medicinal Product Market Key Takeaways
- The market is expected to expand from USD 43.09 billion in 2025 to USD 174.31 billion by 2035, reflecting sustained investment in regenerative medicine.
- Gene therapy medicines accounted for 49.5% of the market, making them the largest product category due to increasing treatment success for inherited diseases.
- North America maintains market leadership through strong biotechnology innovation, favorable research funding, and a growing patient population with rare genetic disorders.
- Asia-Pacific is projected to record the fastest growth as regional governments increase healthcare investment and biotechnology capabilities.
- Rising academic and industry research spending continues to accelerate ATMP discovery, clinical development, and commercialization.
- Regulatory complexity remains one of the primary challenges affecting approval timelines and market entry for new therapies.
Advanced Therapy Medicinal Product Market Scope
| Metrics | Details |
| Market Size (2025) | USD 43.09 Billion |
| Market Size (2035) | USD 174.31 Billion |
| CAGR | 16.80% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | By Type, By Disease Indication |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
For more details on this report – Request for Sample
Advanced Therapy Medicinal Product Market Dynamics: Drivers & Restraints
The increase in the number of research and developmental activities
The increase in the novel approaches to treating genetic disorders and increased investments in the research for developing new drugs and treatment procedures is expected to drive the market growth.
For instance, according to the National Center for Science and Engineering Statistics, it is estimated that Research and development spending by academic institutions totaled $97.8 billion in 2022, an increase of $8.0 billion from 2021
For instance, Urgo launched a $107M artificial skin engineering laboratory novel tissue engineering laboratory to create artificial skin to help the health care professionals in the effective treatment of severe wounds and quickly curing patients. Thus, the increasing research and increase in investments in introducing new products are expected to drive market growth in the forecast period.
Stringent regulations for the approvals
The stringent regulations associated with the approvals of the medicine are expected to decline the market growth. The risks associated with gene corrections and treatments are also a factor that hamper market growth.
Advanced Therapy Medicinal Product Market Opportunities
The commercialization landscape for ATMPs continues to broaden as healthcare providers increasingly adopt personalized treatment strategies.
Biotechnology companies have opportunities to expand manufacturing capacity for gene and cell therapies, while pharmaceutical companies can strengthen product portfolios through licensing agreements and strategic acquisitions. Contract development and manufacturing organizations are also positioned to benefit from increasing outsourcing demand as therapy developers seek scalable production capabilities.
Investors are closely monitoring companies developing therapies for rare genetic disorders, oncology, and regenerative medicine, where clinical differentiation and premium pricing may support attractive long-term returns. Suppliers of viral vectors, cell processing technologies, and specialized manufacturing equipment are also expected to experience rising demand as production volumes increase.
Advanced Therapy Medicinal Product Market Segmentation
The global advanced therapy medicinal product (ATMP) market is segmented based on type, disease indication, and region.
Gene therapy medicines segment accounted for 49.5% of the market share
Gene therapy medicines have been holding a dominant position in the market share. This is due to the increase in genetic disorders and also the efficiency of the treatment to treat the disorder. Gene therapy drugs such as siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA, and miRNA have shown great potential in biomedical applications.
Gene therapy is a new generation of medicine where a functioning gene is delivered to a targeted tissue in the body to produce a missing or nonfunctioning protein. Based on the cells and genes of the individual the medicines that target the incorrect gene are produced. Most of the disease conditions can be cured or prevented by gene therapy medicine.
For instance, according to the NIH report in 2021, it is estimated that genetic therapy medicine management showed 30–40% complete response and 50–60% partial response with a total response rate of 90%–96% in different therapeutic uses. Thus, the above factors are expected to hold the segment in the dominant market share.
Advanced Therapy Medicinal Product Market Regional Outlook
North America Advanced Therapy Medicinal Product Market
North America remains the largest regional market due to its advanced biotechnology ecosystem, strong research infrastructure, and high investment in regenerative medicine.
The growing prevalence of genetic disorders supports continuous research and commercial development. According to CDC data referenced in the source material, approximately 35,000 people in the United States live with cystic fibrosis, while nearly 1,000 new cases are diagnosed annually. In addition, researchers estimated around 18,000 males in the United States were living with hemophilia, with most patients receiving treatment through specialized Hemophilia Treatment Centers. These factors continue to encourage innovation and clinical adoption throughout the region.
Europe Advanced Therapy Medicinal Product Market
Europe benefits from established pharmaceutical manufacturers, increasing investment in regenerative medicine research, and continued innovation in tissue engineering technologies. Companies operating across the region are expanding collaborations to accelerate commercialization of advanced therapies while addressing regulatory requirements for product approval.
Asia-Pacific Advanced Therapy Medicinal Product Market
Asia-Pacific is expected to record the fastest growth throughout the forecast period. Expanding healthcare infrastructure, increasing biotechnology investments, growing clinical research activity, and supportive government initiatives are improving the region's ability to develop and commercialize advanced therapy medicinal products. Rising healthcare expenditure and improving access to innovative treatments further strengthen long-term regional prospects.
Advanced Therapy Medicinal Product Market Competitive Landscape
The leading companies with a significant market share include RHEACELL., BioTissue Technologies GmbH, Mukocell GmbH, Orchard Therapeutics plc., Kite Pharma EU B.V., Bristol-Myers Squibb Pharma EEIG, Novartis Europharm Limited, and Amgen Europe B.V. among others.
Why Purchase the Report?
- To visualize the global advanced therapy medicinal product (ATMP) market segmentation based on type, disease indication, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of advanced therapy medicinal product market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global advanced therapy medicinal product market report would provide approximately 47 tables, 48 figures, and 176 Pages.
Impact Analysis
The COVID-19 pandemic had a moderate effect on the ATMP market. Research priorities temporarily shifted toward COVID-19 therapeutic development, reducing activity across several regenerative medicine programs. Global supply chain disruptions also affected manufacturing operations and clinical development timelines. As research activity normalized, investment in advanced therapies resumed, supporting renewed commercial momentum.
Report Benefits
This report enables stakeholders to:
- Evaluate market opportunities across advanced therapy medicinal product categories.
- Assess growth potential by therapy type, disease indication, and geography.
- Understand competitive positioning and company strategies.
- Support investment planning through market forecasts and commercial analysis.
- Identify emerging research and development trends.
- Evaluate regulatory, pricing, and commercialization considerations influencing long-term market growth.
Target Audience
- Pharmaceutical Manufacturers
- Biotechnology Companies
- Cell and Gene Therapy Developers
- Healthcare Providers
- Research Organizations
- Contract Development and Manufacturing Organizations
- Institutional Investors
- Venture Capital Firms
- Strategy and Business Development Teams
- Procurement Professionals
- Regulatory Consultants
Conclusion
The advanced therapy medicinal product market is positioned for sustained expansion as regenerative medicine transitions from experimental research to broader clinical application. Increasing research investment, strong progress in gene and cell therapy technologies, and growing demand for precision medicine continue to reinforce long-term commercial potential. Although regulatory complexity and manufacturing challenges remain important considerations, organizations capable of delivering clinically validated, scalable, and cost-effective advanced therapies are likely to capture significant opportunities through 2035. Companies, investors, and healthcare stakeholders should closely monitor this market as innovation continues to reshape the future of personalized medicine.
